Can an extra radiation dose keep HER2+ breast cancer at bay?

NCT ID NCT05893966

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study looks at whether adding a tumor bed boost to standard whole breast radiation after breast-conserving surgery helps women with HER2-positive breast cancer. It will track recurrence, survival, and side effects over seven years. The goal is to see if the extra radiation dose improves long-term outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Radiation therapy (whole breast irradiation with or without tumor bed boost)
What this could lead to
If successful, this could refine radiation treatment for HER2+ breast cancer, potentially reducing recurrence while minimizing side effects.
What could go wrong
This is an observational study, not a randomized trial, so results may be influenced by other factors. Radiation can cause side effects like skin irritation or fatigue.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Samsung Medical Center

    RECRUITING

    Seoul, Seoul, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.